Feed ENLV
EN

Enlivex Therapeutics Ltd. ENLV · NASDAQ

$0.20 -1.48% (-$0.00)

Summary

69 / 100 · Bulios Score

What speaks for it

  • The share price is below the Bulios Fair Price.

What to watch

  • It passes only 3 of the 9 points of the Piotroski financial health test.
  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $0.2
P/E today 0.0
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 0.0 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $15 is 7,430% above today's price. 75% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy